Conflict of Interest in Human Subjects Research

Conflict of interest in human subjects research is the narrower, IRB-facing application of the general research-COI concept. It exists where an investigator’s, institution’s, or IRB member’s financial or personal interest could compromise — or reasonably appear to compromise — the design, conduct, oversight, or reporting of a study involving human participants. What makes it a distinct topic is the consequence: the interest has to be resolved before the IRB may approve the protocol, so it sits on the critical path to enrolling the first subject rather than in a parallel disclosure file.

Why human-subjects COI is treated separately

NIH set out the reasoning in Guide notice NOT-OD-00-040, “Financial Conflicts of Interest and Research Objectivity: Issues for Investigators and Institutional Review Boards” (5 June 2000). Its framing is that concerns arise where financial considerations may compromise, or have the appearance of compromising, an investigator’s professional judgment and independence in the design, conduct, or publication of research. The appearance limb is what drives the practice: a management plan is often warranted even where nobody believes actual bias has occurred, because participants’ trust is the thing at stake.

Human-subjects research raises this more sharply than other research because the person bearing the risk is not the person evaluating it. An investigator with an equity stake in the sponsor is asking someone else to accept a physical risk in a study whose success benefits the investigator financially.

The three layers

1. Investigator financial interests — 42 CFR Part 50 Subpart F

For PHS-funded research, the governing rule is 42 CFR Part 50 Subpart F. Its structure is disclosure, then determination, then management:

• A significant financial interest (SFI) is defined at 42 CFR 50.603. For a publicly traded entity, an SFI exists where remuneration received in the preceding twelve months plus the value of any equity interest, aggregated, exceeds $5,000. For a non-publicly traded entity, an SFI exists where remuneration exceeds $5,000 or where the investigator holds any equity interest at all. Intellectual property rights and interests count upon receipt of related income. Reimbursed or sponsored travel related to institutional responsibilities must also be disclosed, with a carve-out for travel sponsored by a federal, state or local government agency, an institution of higher education, an academic teaching hospital, a medical center, or an affiliated research institute.
• A financial conflict of interest (FCOI) is the narrower finding: an SFI that could directly and significantly affect the design, conduct, or reporting of the PHS-funded research. Disclosure is the investigator’s obligation; the FCOI determination is the institution’s.
• Investigator is defined functionally, not by title — the PD/PI and any other person, regardless of title or position, responsible for the design, conduct or reporting of the research, which can include collaborators and consultants.
• Under 42 CFR 50.605(a), before the institution expends any funds under the project, the designated official must review disclosures, determine which SFIs relate to the research, determine whether an FCOI exists, and if so develop and implement a written management plan.
• 42 CFR 50.604 requires the institution to maintain a public, enforced written policy; to train investigators before they engage in PHS-funded research and at least every four years thereafter (plus immediately on policy revision, on joining the institution, or on a finding of non-compliance); to bind subrecipients by written agreement specifying whose policy applies; to keep records for at least three years from the final expenditures report; and to maintain enforcement mechanisms and sanctions.

2. IRB member conflicts — 45 CFR 46.107(d) and 21 CFR 56.107(e)

A separate rule governs the reviewers rather than the researchers. Under 45 CFR 46.107(d), no IRB may have a member participate in the IRB’s initial or continuing review of any project in which the member has a conflicting interest, except to provide information requested by the IRB. FDA’s parallel IRB regulation carries the identical provision at 21 CFR 56.107(e). The practical effect is that a conflicted member may answer questions and then must leave the discussion and the vote — and the minutes need to show it, because the recusal is the evidence that the quorum was properly constituted.

3. FDA financial disclosure — 21 CFR Part 54

For studies supporting a marketing application, 21 CFR Part 54 imposes a different test again, applied at the point of submission rather than at approval. Its definitions set the thresholds: a significant equity interest means any interest whose value cannot readily be determined by reference to public prices, or any equity in a publicly traded corporation exceeding $50,000 during the study and for one year after; significant payments of other sorts means payments to the investigator or institution supporting the investigator’s activities with a monetary value of more than $25,000, exclusive of the costs of conducting the study, over the same window; and compensation affected by the outcome means compensation that could be higher for a favourable result, including equity in the sponsor or royalty-style arrangements. Part 54 reaches the clinical investigator and their spouse and dependent children.

How the pieces fit together in practice

The sequence at most institutions runs: investigator discloses to the COI office; the COI committee determines whether an FCOI exists and, if so, writes a management plan; the plan goes to the IRB; the IRB reviews the protocol and the plan together under its general approval criteria at 45 CFR 46.111; and enrolment cannot begin until both are approved. Three points are worth isolating because they are where the process most often goes wrong:

• An IRB cannot substitute for the COI committee, and vice versa. They answer different questions — whether the interest is manageable, and whether the study as managed is approvable.
• Thresholds differ between regimes. A $30,000 payment is not a Part 54 “significant payment of other sorts” issue at $25,000 but plainly exceeds the $5,000 PHS SFI threshold. An interest can be reportable under one rule and not another, and the answer to “do we have a conflict?” depends on which rule is being asked about.
• Study payments are not themselves the conflict. Per-subject payments covering the direct costs of running the trial are disclosed as a funding source; they do not on their own create an SFI.

Typical management measures

42 CFR 50.605(a) requires the plan to specify the actions taken to manage the conflict, and to “manage” is defined at 50.603 as taking action to address the FCOI, which can include reducing or eliminating it, to ensure so far as possible that design, conduct and reporting are free from bias. Common measures, in rough order of intrusiveness:

• Disclosure of the interest to participants in the informed consent document, in plain language naming the type of interest.
• Disclosure in publications and presentations.
• Independent monitoring of the research, or independent oversight of the consent process by someone with no interest in the study.
• Modification of the research plan, or removal of the conflicted individual from specified parts of the study — typically consent, eligibility determination, or outcome adjudication.
• Divestiture of the interest or severance of the relationship, where nothing lesser will do.

Frequently Asked Questions

What should an IRB member do if they have a conflict of interest with a study under review?

Under 45 CFR 46.107(d) — and, for FDA-regulated studies, 21 CFR 56.107(e) — an IRB member with a conflicting interest in a specific protocol — for example, serving as co-investigator or holding a financial stake in the sponsor — may answer questions the other members ask about the study but must not otherwise participate in reviewing or voting on it. This is handled at the point of IRB decision-making, separately from the institutional financial-conflict-of-interest process used for investigator interests.

What counts as a financial conflict of interest for a researcher in human subjects research?

A financial conflict typically involves a personal stake tied to the outcome of the study, such as equity, royalties, or consulting fees connected to the study sponsor or the technology being tested. Standard per-subject payments that only cover the direct costs of running a trial — staff time, supplies, monitoring visits — are disclosed as a funding source but do not, on their own, trigger the significant-financial-interest review and management-plan requirement.

Who reviews a researcher’s conflict of interest before an IRB will approve a study?

The institution’s conflict-of-interest committee reviews the disclosed financial interest first and, where warranted, develops a management plan — such as independent monitoring of the consent process, disclosure to subjects, or removing the conflicted investigator from part of the study. That plan is then communicated to the IRB, which reviews it alongside the protocol under its general approval criteria (45 CFR 46.111); the study cannot enroll subjects until the IRB has approved both the protocol and the management plan.

Do research participants have to be told about a researcher’s conflict of interest?

Where a management plan calls for disclosure, yes — the financial relationship is typically summarized in the informed consent document in plain language, naming the type of interest (e.g., equity, royalty, consulting fees) rather than requiring subjects to interpret a compliance filing. NIH Notice NOT-OD-00-040 frames this as letting a reasonable person, including a prospective subject, judge whether the interest could have influenced the study’s design or conduct.

How is a conflict of interest in human subjects research different from a general research conflict of interest?

It is a narrower, IRB-facing application of the broader concept: general institutional disclosure and management happens under 42 CFR Part 50 Subpart F, but human-subjects research adds a second layer in which the IRB itself must see and act on the outcome of that review before the study may proceed, tied directly to the approval decision rather than only to institutional disclosure. See conflict of interest for the general concept.